Tarsons Products Past Earnings Performance
Past criteria checks 1/6
Tarsons Products's earnings have been declining at an average annual rate of -10.3%, while the Life Sciences industry saw earnings growing at 25.2% annually. Revenues have been growing at an average rate of 3.1% per year. Tarsons Products's return on equity is 5.6%, and it has net margins of 9.8%.
Key information
-10.3%
Earnings growth rate
-11.3%
EPS growth rate
| Life Sciences Industry Growth | 11.2% |
| Revenue growth rate | 3.1% |
| Return on equity | 5.6% |
| Net Margin | 9.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Tarsons Products makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,516 | 345 | 622 | 0 |
| 30 Jun 24 | 3,186 | 371 | 512 | 0 |
| 31 Mar 24 | 2,964 | 426 | 489 | 0 |
| 31 Dec 23 | 2,727 | 551 | 423 | 0 |
| 30 Sep 23 | 2,723 | 613 | 409 | 0 |
| 30 Jun 23 | 2,772 | 700 | 399 | 0 |
| 31 Mar 23 | 2,832 | 807 | 391 | 0 |
| 31 Dec 22 | 2,887 | 874 | 365 | 0 |
| 30 Sep 22 | 2,981 | 927 | 356 | 0 |
| 30 Jun 22 | 3,029 | 961 | 345 | 0 |
| 31 Mar 22 | 3,008 | 1,007 | 338 | 0 |
| 31 Dec 21 | 2,858 | 948 | 314 | 0 |
| 30 Jun 21 | 2,581 | 867 | 286 | 0 |
| 31 Mar 21 | 2,313 | 689 | 267 | 0 |
| 31 Mar 20 | 1,750 | 385 | 206 | 0 |
| 31 Mar 19 | 1,886 | 399 | 164 | 0 |
Quality Earnings: 543399 has high quality earnings.
Growing Profit Margin: 543399's current net profit margins (9.8%) are lower than last year (22.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 543399's earnings have declined by 10.3% per year over the past 5 years.
Accelerating Growth: 543399's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 543399 had negative earnings growth (-43.7%) over the past year, making it difficult to compare to the Life Sciences industry average (37.9%).
Return on Equity
High ROE: 543399's Return on Equity (5.6%) is considered low.